LHRH AND ITS ANALOGUES
Basic and clinical aspects

Proceedings of the International Symposium on LHRH and its Analogues
Quebec City, June 28-30, 1984

Editors:
Fernand Labrie, Alain Bélanger, André Dupont
Department of Molecular Endocrinology,
Centre Hospitalier de l’Université Laval,
Quebec, Canada

Excerpta Medica, Amsterdam - New York - Oxford
Contents

OPENING LECTURE

LH-RH analogs in contraception and cancer
   A.V. Schally 3

1. Chemistry of LHRH Agonists and Antagonists

Design of cyclic GnRH antagonists

Long acting LHRH agonists and antagonists

Design and synthesis of LH-RH agonists and antagonists
   R. Geiger 36

2. Delivery Systems for Controlled Release

An injectable biodegradable controlled release delivery system for nafarelin acetate
   L.M. Sanders, G.I. McRae, K.M. Vitale, B.H. Vickery and J.S. Kent 53

A pharmaceutical approach to long-term therapy with peptides
   W. Petri, R. Seidel and J. Sandow 63

Relation between biological activities and blood levels of LH-RH or its analogues by different routes of administration in rats
   I. Yamazaki 77

3. Preclinical Studies: Pharmacology, Physiology and Toxicology

Comparison of LHRH agonist and antagonist: Antifertility and therapeutic developments
   A. Corbin, F.J. Bex and R.C. Jones 95

Pharmacokinetics and metabolism of LHRH agonists, clinical aspects
   J. Sandow, G. Jerabek-Sandow, B. Krauss and M. Schmidt-Gollwitzer 123
4. Animal Models

The dog, a good model for the study of LHRH agonists as blockers of androgen secretion and potential contraceptives
A. Bélanger, Y. Tremblay, D. Lacoste, M. Giasson, A. Dupont and F. Labrie

Interactions between an LHRH analogue and cancer chemotherapeutic agents at the testicular level
J.C. Goodpasture, K. Bergstrom, D.P. Waller and B.H. Vickery

Manipulation of the pituitary-ovarian axis in the stumptailed macaque by LHRH antibodies, LHRH agonist and antagonist analogues
H.M. Fraser

The effects of LH-RH inhibitory analogues in the non-human primate. Basic studies in contraception and their direct applications for future clinical uses in both sexes
R.H. Asch

Studies on the mechanism of infertility associated with endometriosis and the effect of an LHRH agonist (Histrelin; ORF 17070) in an animal model for endometriosis
D.W. Hahn, R. Carraher, R. Foldesy and J.L. McGuire

LHRH analogs and experimental prostatic cancer models
F. Bex and A. Corbin

Phospholipid turnover and GnRH action in the pituitary and gonads
Z. Naor, J. Molcho, J. Hermon, M. Zilberstein, H. Zakut and N. Dekel

5. Female Contraception

Superagonists of LHRH for contraception in women
S.J. Nillius, C. Bergquist, J.A. Gudmundsson and L. Wide

6. Male Contraception

LHRH agonists and antagonists for male fertility control: Experiments in monkeys and men
E. Nieschlag, F.B. Akhtar, T. Schürmeyer and G. Weinbauer

Hormonal effects of GnRH agonist in the human male: An approach to male contraception using combined androgen and GnRH agonist treatment
R.S. Swerdloff and S. Bhasin
7. Prostate Cancer

Subcutaneous administration of ‘Zoladex’ (ICI 118,630 - An LH-RH analogue) in advanced prostatic cancer
   R.J. Donnelly, R.C. Cotton, S.H. Ellis and D. Richards 305

Clinical response and safety of LHRH agonist treatment in prostatic carcinoma

Advanced prostatic carcinoma: A therapeutic challenge
   G. Tolis and M. Koutsilieris 326

GnRH superagonist treatment of prostate cancer: Hormonal effects with and without an androgen biosynthesis inhibitor
   R.J. Santen, H.F. English and B.A. Warner 336

Three years of experience with the GnRH-analogue buserelin in 100 patients with advanced prostatic cancer
   U.K. Wenderoth and G.H. Jacobi 349

Response and relapse in patients with prostatic cancer treated with buserelin

Complete androgen blockade at start of treatment causes a dramatic improvement of survival in advanced prostate cancer
   F. Labrie, A. Dupont, A. Bélanger, Y. Lacoursière and members of the Laval University Prostate Cancer Program 368

8. Endometriosis

Efficacy and safety of LHRH agonist treatment in 10 patients with endometriosis
   A. Lemay, R. Maheux, N. Faure, C. Jean and A.T.A. Fazekas 383

Reversible hypogonadism induced by a luteinizing hormone releasing hormone (LHRH) agonist (buserelin) as a new therapeutic approach for leiomyomata uteri
   R. Maheux, C. Guilloteau, A. Lemay, A. Bastide and A.T.A. Fazekas 396
9. Breast Cancer and Precocious Puberty

Subcutaneous and intranasal D-ser(TBU)\textsuperscript{6} EA\textsuperscript{10} LHRH (buserelin) in the management of precocious puberty

\textit{F.J. Holland, L. Fishman, A. Luder, D.C. Costigan, M. Jenner, G. Wielgosz and A.T.A. Fazekas}

Long-term treatment with the LHRH-agonist buserelin (HOE 766) for metastatic breast cancer in single and combined drug regimens

\textit{J.G.M. Klijn and F.H. de Jong}

LHRH analog effect on pubertal development, growth and maturation in precocious puberty


10. Stimulation of Gonadal Functions

Pulsatile administration of Gn-RH in hypothalamic amenorrhea

\textit{G. Leyendecker and L. Wildt}

Induction of ovulation with LHRH - Problems, indications and contraindications


The results of long-term GnRH administration in idiopathic hypogonadotropic hypogonadism

\textit{W.F. Crowley Jr and D. Spratt}

Does long-term treatment with buserelin improve the fertility chances of cryptorchid testes?

\textit{F. Hadžiselimović, B. Hoecht, B. Herzog and J. Girard}

11. Drug Regulatory Aspects of LHRH Agonists and Antagonists

Trends in drug development with special reference to the testing of LHRH analogues

\textit{J.L. Gueriguian, C.A. Schaffenburg, Y.-Y.H. Chiu and V. Berliner}

Canadian drug regulations and peptide hormonal pharmaceuticals

\textit{O.J. Lucis}

LHRH agonists and antagonists. Aspects of their safety and efficacy

\textit{K.-W. von Eickstedt}

Index of authors

Subject index